Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study

Area of Science:

• Rheumatology
• Cardiology
• Pharmacology

Background:

• Tocilizumab is a biologic treatment for inflammatory conditions like rheumatoid arthritis and juvenile idiopathic arthritis.
• Cardiovascular risk is a concern in patients with chronic inflammatory diseases.
• The effect of tocilizumab on lipid profiles and cardiovascular events requires further investigation.

Purpose of the Study:

• To evaluate the impact of initiating tocilizumab on lipid profiles.
• To assess the correlation between lipid profile changes and cardiovascular events in patients treated with tocilizumab.
• To compare these effects with other biologic treatments.

Main Methods:

• Retrospective cohort study utilizing data from King Faisal Specialist Hospital & Research Centre (2014-2019).
• Included adult patients (≥18 years) with rheumatoid arthritis or juvenile idiopathic arthritis initiated on tocilizumab or other biologics (anti-TNFs, Rituximab).
• Minimum follow-up of 6-12 months up to 3-5 years; excluded patients with pre-existing cardiovascular disease or under 18.

Main Results:

• A single cardiovascular mortality occurred in the tocilizumab group.
• Fifty percent of tocilizumab patients achieved high cholesterol (≥5.2 mmol/L) and LDL (≥3.37 mmol/L) levels by 36 months, significantly faster than controls (60 months; P=0.001).
• No significant difference in statin use, but higher mean atorvastatin dose in the tocilizumab group (20.6mg vs. 16.6mg; P=0.03).

Conclusions:

• The study found no evidence of increased cardiovascular risk associated with tocilizumab-induced hyperlipidemia.
• Tocilizumab treatment led to quicker elevations in cholesterol and LDL levels compared to controls.
• Further research may be needed to fully elucidate the long-term cardiovascular implications.